{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.6","upperLimit":"48.3","value":"39"},{"groupId":"OG001","lowerLimit":"39.8","upperLimit":"61.3","value":"50.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is defined as a \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.","reportingStatus":"POSTED","timeFrame":"Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)","title":"ORR Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}